MCK vs SGRY
MCK: McKesson is a healthcare services giant that orchestrates the entire pharmaceutical and medical supply chain—from drug distribution and specialty oncology care to technology platforms that connect patients, pharmacies, and providers. SGRY: Surgery Partners owns and operates a national network of over 200 ambulatory surgery centers, surgical hospitals, and physician practices focused on delivering cost-effective outpatient surgical care.
Side-by-side fundamentals
| Metric | MCK | SGRY | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $850.06 | $15.17 | |
| Market cap as of 2026-07-31 | $102.2B | $2.0B | |
| P/E as of 2026-07-31 | 21.33 | n/a | |
| PEG as of 2026-07-31 | 1.50 | 0.20 | SGRY lower |
| Net margin as of 2026-07-31 | +1.2% | -2.2% | MCK higher |
| Gross margin as of 2026-07-31 | +3.6% | +25.2% | SGRY higher |
| Operating margin as of 2026-07-31 | +1.5% | +11.4% | SGRY higher |
| ROE as of 2026-07-31 | +39.4% | -4.6% | MCK higher |
| ROA as of 2026-07-31 | +5.7% | -1.0% | MCK higher |
| Debt / equity as of 2026-07-31 | 1.29 | 2.20 | MCK lower |
| Revenue growth (YoY) as of 2026-07-31 | +12.4% | -20.5% | MCK higher |
| Revenue CAGR (3y) SEC XBRL | +13.4% | +59.1% | SGRY higher |
| Dividend yield as of 2026-07-31 | +0.4% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-07-31 | 0.31 | 1.93 | |
| 1-year return as of 2026-07-27 close | +19.4% | -28.6% | MCK higher |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.